Primary immunodeficiencies are a group of different disorders in which part of the body's immune system (mainly cells and proteins) is missing or does not function normally. As per researchers, estimated more than 300 different kinds of primary immunodeficiency disease (PIDD). The immune system is composed of white blood cells made in the bone marrow which protect and defend against attacks by foreign invaders such as bacteria, fungi, and germs. Antibodies and Complement are proteins that are made in response to infection or immunization and helps to fight against infections and plays a protective role in the immune system. In the most common primary immunodeficiency diseases, different forms of cells or proteins are missing or do not function which results in severe infections and/or infections that are unusually hard to cure. These infections may attack the respiratory system, the brain or spinal cord, the ears, skin, or in the urinary or gastrointestinal tracts. In some instances, primary immunodeficiency diseases target specific and/or multiple organs, glands, cells, and tissues. For example, heart defects are present in some primary immunodeficiency diseases.
This report contains market size and forecasts of Primary Immunodeficiency Therapeutic in Global, including the following market information:
Global Primary Immunodeficiency Therapeutic Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Primary Immunodeficiency Therapeutic market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Immunoglobulin Replacement Therapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Primary Immunodeficiency Therapeutic include Baxter International, Takeda Pharmaceutical, CSL Limited, Octapharma, Kedrion Biopharma, Bio Products Laboratory, LFB group, Grifols and Lupin Pharmaceuticals. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Primary Immunodeficiency Therapeutic companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Primary Immunodeficiency Therapeutic Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Primary Immunodeficiency Therapeutic Market Segment Percentages, by Type, 2021 (%)
Immunoglobulin Replacement Therapy
Stem Cell or Bone Marrow Transplantation
Antibiotic Therapy
Gene Therapy
Others
Global Primary Immunodeficiency Therapeutic Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Primary Immunodeficiency Therapeutic Market Segment Percentages, by Application, 2021 (%)
Antibody Deficiency
Cellular Immunodeficiency
Innate Immune Disorders
Others
Global Primary Immunodeficiency Therapeutic Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Primary Immunodeficiency Therapeutic Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Primary Immunodeficiency Therapeutic revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Primary Immunodeficiency Therapeutic revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Baxter International
Takeda Pharmaceutical
CSL Limited
Octapharma
Kedrion Biopharma
Bio Products Laboratory
LFB group
Grifols
Lupin Pharmaceuticals